?
Xenetic Biosciences plc
(the "Company")
Exercise of Options
Xenetic Biosciences plc (AIM: "XEN"), today announces that it has applied for 173,059 new ordinary shares of 0.5 pence each to be admitted to trading on AIM as a result of the exercise of an employee option award. Admission of the new shares is expected to take place on 10 January 2014.
The Company's issued share capital, as stated in the RNS on 6 January 2014, consists of 408,048,487 ordinary shares each with one voting right. The Company does not hold any ordinary shares in treasury.
Enquiries:
Xenetic Biosciences plc | www.xeneticbio.com |
M. Scott Maguire, Chief Executive Officer | +44 (0)20 3021 1500 |
Colin Hill, Chief Financial Officer | |
London Bridge Capital (Financial Adviser to Xenetic) | +44 (0)7912 201639 |
Adam Hart | |
N+1 Singer(Nominated Adviser & Broker) | +44 (0)20 7496 3000 |
Aubrey Powell | |
Walbrook PR | +44 (0)20 7933 8780 |
Mike Wort (Media Enquiries) | mike.wort@walbrookpr.com |
Paul Cornelius (Investor Enquiries) | paul.cornelius@walbrookir.com |
This information is provided by RNS
distributed by
|